Heron Therapeutics (NASDAQ:HRTX) Stock Rating Upgraded by BidaskClub
A number of other analysts also recently weighed in on HRTX. Zacks Investment Research downgraded Heron Therapeutics from a hold rating to a sell rating in a report on Thursday, May 9th. Stifel Nicolaus reiterated a buy rating and set a $38.00 price target on shares of Heron Therapeutics in a report on Monday, August 5th. ValuEngine upgraded Heron Therapeutics from a sell rating to a hold rating in a report on Thursday, August 1st. Northland Securities reiterated a buy rating and set a $55.00 price target on shares of Heron Therapeutics in a report on Monday, August 5th. Finally, Cowen reiterated a buy rating on shares of Heron Therapeutics in a report on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. Heron Therapeutics presently has an average rating of Hold and an average price target of $52.67.
Shares of Heron Therapeutics stock opened at $18.17 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.70 and a current ratio of 4.01. The stock’s 50-day simple moving average is $18.04. Heron Therapeutics has a 1-year low of $15.68 and a 1-year high of $41.10. The firm has a market cap of $1.46 billion, a P/E ratio of -7.45 and a beta of 1.49.
In other news, Director John Poyhonen bought 3,000 shares of Heron Therapeutics stock in a transaction dated Wednesday, May 22nd. The stock was bought at an average cost of $17.55 per share, for a total transaction of $52,650.00. Following the purchase, the director now directly owns 13,000 shares in the company, valued at approximately $228,150. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 12.56% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of HRTX. Clearbridge Investments LLC grew its stake in shares of Heron Therapeutics by 153.4% in the 1st quarter. Clearbridge Investments LLC now owns 2,180,577 shares of the biotechnology company’s stock valued at $53,293,000 after buying an additional 1,320,025 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Heron Therapeutics by 319.0% in the 1st quarter. JPMorgan Chase & Co. now owns 889,696 shares of the biotechnology company’s stock valued at $21,744,000 after buying an additional 677,354 shares during the period. Norges Bank acquired a new stake in shares of Heron Therapeutics in the 4th quarter valued at about $13,679,000. WS Management Lllp acquired a new stake in shares of Heron Therapeutics in the 1st quarter valued at about $11,174,000. Finally, C WorldWide Group Holding A S grew its stake in shares of Heron Therapeutics by 178.5% in the 2nd quarter. C WorldWide Group Holding A S now owns 702,069 shares of the biotechnology company’s stock valued at $13,051,000 after buying an additional 450,000 shares during the period.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Article: Why is the price target of stocks important?
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.